EGFR and cancer: Both S442I and L658Qhave been detected in cancer samples, but, to the best of our knowledge,have not been shown to confer ligand-independent EGFR activation.Mechanistic studies at atomic scale using molecular dynamics (MD)simulations suggest hydrogen bonding within the hydrophobic environmentof the plasma membrane as a potential molecular mechanism for L658Q-mediateddimerization and thus activation.